News

Cyclo Therapeutics Announces Proposed Public Offering of Common Stock

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH, CYTHW) ("Cyclo Therapeutics" of the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with...

Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event

Live moderated video webcast discussion with N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer on Tuesday, November 16th at 11:00 AM ET GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the...

Trappsol® Cyclo™ is not currently approved for any indication.

Third-party websites are provided for convenience only. Cyclo Therapeutics, Inc. does not approve of, or endorse any of the content. Cyclo Therapeutics, Inc. does not maintain, control or monitor the content of third-party websites in any way.